Sensei Biotherapeutics Inc (SNSE)
NGM · Healthcare · Biotechnology
Closing price as of 2026-07-17 · Source: TEK2day Finance
Key Metrics
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.2M | -4.9M | -5.0M | -170.6M |
| Net Income | -4.9M | -4.6M | -4.7M | -170.2M |
| Diluted EPS | $-3.91 | $-3.62 | $nan | $-131.45 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -50.2M | -37.1M | -31.7M | -22.3M |
| Net Income | -48.6M | -34.1M | -30.2M | -21.1M |
| Diluted EPS | $-31.60 | $-24.40 | $-24.00 | $-16.72 |